-
Mashup Score: 0FDA considers temporary cancer drug imports from unapproved companies to ease U.S. shortage - 11 month(s) ago
Shortages of cisplatin and carboplatin, bedrock cancer treatments, have forced some hospitals to ration the drugs.
Source: CNBCCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Mark Cuban's Pharmacy Adds Another Onc Drug: Capecitabine - 11 month(s) ago
But will current drug shortages limit the supply of this generic cancer drug and others sold by Cuban’s Cost Plus Drug Company?
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In late April, the Mark Cuban Cost Plus Drug Company added another oncology drug to its formulary: capecitabine. https://t.co/JDhNoRc1hz #OncTwitter #TwitteRx
-
-
Mashup Score: 2Widespread Prescribing of Stimulants With Other CNS Meds - 11 month(s) ago
A large proportion of US adults prescribed Schedule II stimulants are simultaneously receiving other CNS agents, including benzodiazepines, opioids, and antidepressants.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
A large proportion of US adults who are prescribed Schedule II stimulants are simultaneously receiving other CNS agents including benzodiazepines, opioids, and antidepressants — a potentially dangerous practice. #TwitteRx https://t.co/bzlssXCzW7
-
-
Mashup Score: 2Expunging 'Penicillin Allergy': Your Questions Answered - 11 month(s) ago
Dr Vega responds to reader questions about delabeling penicillin allergy in a patient who reports a childhood rash after taking amoxicillin.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
Dr Vega responds to reader questions about delabeling #penicillin allergy in a patient who reports a childhood rash after taking #amoxicillin. #TwitteRx #penicillinallergy https://t.co/PTX9R9GQaG
-
-
Mashup Score: 5Peresolimab Shows Efficacy in Patients With RA - 11 month(s) ago
Only patients taking peresolimab 700 mg had a significantly greater change in Disease Activity Score in 28 Joints based on the C-reactive protein level (DAS28-CRP), compared with placebo after 12 weeks.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
Peresolimab shows efficacy in patients with RA #rheumatoidarthritis #TwitteRx https://t.co/Wdx4PMAjHe https://t.co/OymVXBb1YB
-
-
Mashup Score: 0Annual Costs of Lecanemab Estimated to Be Upwards of $2B - 12 month(s) ago
A new cost analysis suggests that annual Medicare spending could increase by $2 to $5 billion if Medicare expands coverage of the antidementia medicine.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
Annual costs of lecanemab estimated to be upwards of $2B #dementia #TwitteRx #NeuroTwitter https://t.co/f3fAAif7dy https://t.co/RiEZzJ8ROa
-
-
Mashup Score: 0Medications That Scare Me - 12 month(s) ago
Many medications can cause cardiac symptoms and other serious side effects in elderly patients.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
➡️ Many medications can cause cardiac symptoms and other serious side effects in elderly patients. #TwitteRx #MedTwitter https://t.co/tzqj5hAKF8
-
-
Mashup Score: 0
Pharmacist-led care models have become increasingly popular in recent years, especially in the management of chronic diseases. In the…
Source: aahivm.orgCategories: Infectious Disease, Latest HeadlinesTweet-
Save the date and register to attend! Details and registration: https://t.co/tKx88pSg2w #Pharmacist #TwitteRx #PrEP #HIVPrEP #PEP #PharmD https://t.co/3ZOE1dbup4
-
-
Mashup Score: 11Senators Call Out PBMs, Drugmakers for High Prescription Drug Costs - 12 month(s) ago
This ‘is a moral issue,’ Sen. Bernie Sanders said during the hearing
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
"Let's be clear, while Americans pay outrageously high prices for prescription drugs, the pharmaceutical companies and the PBMs make enormous profits every year," said @SenSanders. #TwitteRx #MedTwitter https://t.co/aTvIkaZXPR
-
-
Mashup Score: 0New HER2 Drug for Breast Cancer Stalled by FDA - 12 month(s) ago
The FDA said it needs more data the new antibody-drug conjugate (ADC) trastuzumab duocarmazine for use in advanced or metastatic breast cancer.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
A new drug for #breastcancer that was approaching the market in the US has been stalled. #TwitteRx https://t.co/2qHPgoPU06
-
To ease the ongoing shortage of some #cancer drugs, @US_FDA is considering temporary importation of products not currently approved for use in the US #OncTwitter #NurseTwitter #OncoPharm #TwitteRx #drugshortages https://t.co/lQJWbBcaZF